Skip to main content

03.02.2016 | Onkologie | Online-Artikel

Disease progression on EGFR TKI therapy: what to do after erlotinib, gefitinib and afatinib?

Figure 1: Relative frequencies of mechanisms of acquired resistance in EGFR-mutation-positive tumours